{"success":true,"data":{"pressRelease":{"id":"75758","rtpr_id":"nPnZ1Zjca","ticker":"EMBC","exchange":"NASDAQ","all_tickers":["EMBC"],"title":"Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS","author":"PR Newswire","published_at":"2026-06-29T19:26:00.218Z","article_body":"Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS\n\nPR Newswire\n\nSAN FRANCISCO, June 29, 2026\n\nSAN FRANCISCO, June 29, 2026 /PRNewswire/ -- Embecta Corp. (NASDAQ: EMBC)\nfaces a securities class action lawsuit, which seeks to represent investors\nwho purchased or acquired Embecta common stock between November 25, 2025 and\nMay 4, 2026. The lawsuit follows the company's disastrous Q2 2026 earnings\nreport, apparently at odds with prior narrative, which triggered a massive\nselloff in the stock and analysts' questions.\n\nThese developments have prompted national shareholder rights firm Hagens\nBerman to open an investigation into claims that Embecta violated the federal\nsecurities laws.\n\nThe firm encourages Embecta investors who suffered substantial losses to\nsubmit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=3696488131&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fembc&a=submit+your+losses+now)\n.\n\nClass Period: Nov. 25, 2025 – May 4, 2026\nLead Plaintiff Deadline: Aug. 17, 2026\nVisit: www.hbsslaw.com/investor-fraud/embc\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=1519534229&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fembc&a=www.hbsslaw.com%2Finvestor-fraud%2Fembc)\n\nContact the Firm Now: EMBC@hbsslaw.com (mailto:EMBC@hbsslaw.com)\n                                       844-916-0895\n\nEmbecta Corp. (EMBC) Securities Class Action:\n\nEmbecta is a global medical device company whose core business product is pen\nneedles – sterile, single-use, medical devices, designed to be used in\nconjunction with pen injectors that inject insulin or other diabetes\nmedications. In the past, pen needle revenues have comprised over 70% of the\ncompany's total revenues.\n\nThe litigation's primary focus is on the propriety of Embecta's Class Period\nrepeated assurances that \"insulin pens have been stable […] showing the\nunderlying resilience and the durability of that portfolio[]\" and \"our pen\nneedle business is incredibly resolute.\" This narrative formed the basis for\nthe company's February 5, 2026 guidance reiterating 2026 adjusted EPS of $2.80\n- $3.00.  The company also touted maintenance of its dividend within its\ncapital allocation plans as a return of capital to shareholders.\n\nThe complaint alleges the company's assurances and guidance were misleading\nwhen given because Embecta knew or recklessly disregarded that weaknesses in\nthe pen needle market was likely to significantly disrupt the company's annual\nguidance and Q2 results.\n\nOn May 5, 2026, investors' expectations vanished. That day, Embecta reported\nQ2 2026 adjusted EPS of $0.27, a staggering sequential and year-over-year\ndecline of about 61%. In contrast to the company's assurances of stability,\nresilience, and durability, Embecta's pen needles revenues also suffered\nmassive sequential and year-over-year declines. Of additional concern, Embecta\nslashed its 2026 adjusted EPS guidance to $1.55 - $1.75, or down roughly 43%\nat the mid-point, and reduced its dividend by 93% to just $0.01.\n\nIn response, the market sent the price of Embecta shares tumbling, with one\nprominent analyst who downgraded the company highlighting Embecta management's\n\"need to rebuild investor credibility on commercial execution and the\nprofitability outlook.\"\n\n\"Our investigation is focused the extent to which and when Embecta and its\nmanagement knew about pen needle and U.S. business revenue headwinds, and\nwhether they were sufficiently transparent about those risks,\" said Reed\nKathrein\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=1210978566&u=https%3A%2F%2Fwww.hbsslaw.com%2Fattorneys%2Freed-kathrein&a=Reed+Kathrein)\n, the Hagens Berman partner leading the firm's investigation.\n\nIf you invested in Embecta and have substantial losses, or have knowledge that\nwill assist the firm's investigation, submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=3696488131&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fembc&a=submit+your+losses+now)\n»\n\nIf you'd like more information and answers to other frequently asked questions\nabout the Embecta case and the firm's investigation, read more »\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=1133092411&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fembecta-corp-embc-securities-class-action&a=read+more+%C2%BB)\n\nWhistleblowers: Persons with non-public information regarding Embecta should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email EMBC@hbsslaw.com (mailto:EMBC@hbsslaw.com) .\n\nAbout Hagens Berman\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=3556533090&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=About+Hagens+Berman)\n\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found\nat hbsslaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=910462555&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=hbsslaw.com)\n. Follow the firm for updates and news at @ClassActionLaw\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=215564629&u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&a=%40ClassActionLaw)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/embecta-corp-embc-faces-securities-class-action-for-allegedly-concealing-competitive-threats-to-pen-needle-business----hbss-302813452.html\n(https://www.prnewswire.com/news-releases/embecta-corp-embc-faces-securities-class-action-for-allegedly-concealing-competitive-threats-to-pen-needle-business----hbss-302813452.html)\n\nSOURCE Hagens Berman Sobol Shapiro LLP\n\n\n\nReed Kathrein, 844-916-0895\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1117217/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2743827\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnZ1Zjca","title":"Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS","author":"PR Newswire","ticker":"EMBC","created":"2026-06-29T19:26:00.218Z","tickers":["EMBC"],"exchange":"NASDAQ","article_body":"Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS\n\nPR Newswire\n\nSAN FRANCISCO, June 29, 2026\n\nSAN FRANCISCO, June 29, 2026 /PRNewswire/ -- Embecta Corp. (NASDAQ: EMBC)\nfaces a securities class action lawsuit, which seeks to represent investors\nwho purchased or acquired Embecta common stock between November 25, 2025 and\nMay 4, 2026. The lawsuit follows the company's disastrous Q2 2026 earnings\nreport, apparently at odds with prior narrative, which triggered a massive\nselloff in the stock and analysts' questions.\n\nThese developments have prompted national shareholder rights firm Hagens\nBerman to open an investigation into claims that Embecta violated the federal\nsecurities laws.\n\nThe firm encourages Embecta investors who suffered substantial losses to\nsubmit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=3696488131&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fembc&a=submit+your+losses+now)\n.\n\nClass Period: Nov. 25, 2025 – May 4, 2026\nLead Plaintiff Deadline: Aug. 17, 2026\nVisit: www.hbsslaw.com/investor-fraud/embc\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=1519534229&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fembc&a=www.hbsslaw.com%2Finvestor-fraud%2Fembc)\n\nContact the Firm Now: EMBC@hbsslaw.com (mailto:EMBC@hbsslaw.com)\n                                       844-916-0895\n\nEmbecta Corp. (EMBC) Securities Class Action:\n\nEmbecta is a global medical device company whose core business product is pen\nneedles – sterile, single-use, medical devices, designed to be used in\nconjunction with pen injectors that inject insulin or other diabetes\nmedications. In the past, pen needle revenues have comprised over 70% of the\ncompany's total revenues.\n\nThe litigation's primary focus is on the propriety of Embecta's Class Period\nrepeated assurances that \"insulin pens have been stable […] showing the\nunderlying resilience and the durability of that portfolio[]\" and \"our pen\nneedle business is incredibly resolute.\" This narrative formed the basis for\nthe company's February 5, 2026 guidance reiterating 2026 adjusted EPS of $2.80\n- $3.00.  The company also touted maintenance of its dividend within its\ncapital allocation plans as a return of capital to shareholders.\n\nThe complaint alleges the company's assurances and guidance were misleading\nwhen given because Embecta knew or recklessly disregarded that weaknesses in\nthe pen needle market was likely to significantly disrupt the company's annual\nguidance and Q2 results.\n\nOn May 5, 2026, investors' expectations vanished. That day, Embecta reported\nQ2 2026 adjusted EPS of $0.27, a staggering sequential and year-over-year\ndecline of about 61%. In contrast to the company's assurances of stability,\nresilience, and durability, Embecta's pen needles revenues also suffered\nmassive sequential and year-over-year declines. Of additional concern, Embecta\nslashed its 2026 adjusted EPS guidance to $1.55 - $1.75, or down roughly 43%\nat the mid-point, and reduced its dividend by 93% to just $0.01.\n\nIn response, the market sent the price of Embecta shares tumbling, with one\nprominent analyst who downgraded the company highlighting Embecta management's\n\"need to rebuild investor credibility on commercial execution and the\nprofitability outlook.\"\n\n\"Our investigation is focused the extent to which and when Embecta and its\nmanagement knew about pen needle and U.S. business revenue headwinds, and\nwhether they were sufficiently transparent about those risks,\" said Reed\nKathrein\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=1210978566&u=https%3A%2F%2Fwww.hbsslaw.com%2Fattorneys%2Freed-kathrein&a=Reed+Kathrein)\n, the Hagens Berman partner leading the firm's investigation.\n\nIf you invested in Embecta and have substantial losses, or have knowledge that\nwill assist the firm's investigation, submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=3696488131&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fembc&a=submit+your+losses+now)\n»\n\nIf you'd like more information and answers to other frequently asked questions\nabout the Embecta case and the firm's investigation, read more »\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=1133092411&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fembecta-corp-embc-securities-class-action&a=read+more+%C2%BB)\n\nWhistleblowers: Persons with non-public information regarding Embecta should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email EMBC@hbsslaw.com (mailto:EMBC@hbsslaw.com) .\n\nAbout Hagens Berman\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=3556533090&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=About+Hagens+Berman)\n\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found\nat hbsslaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=910462555&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=hbsslaw.com)\n. Follow the firm for updates and news at @ClassActionLaw\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4721816-1&h=215564629&u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&a=%40ClassActionLaw)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/embecta-corp-embc-faces-securities-class-action-for-allegedly-concealing-competitive-threats-to-pen-needle-business----hbss-302813452.html\n(https://www.prnewswire.com/news-releases/embecta-corp-embc-faces-securities-class-action-for-allegedly-concealing-competitive-threats-to-pen-needle-business----hbss-302813452.html)\n\nSOURCE Hagens Berman Sobol Shapiro LLP\n\n\n\nReed Kathrein, 844-916-0895\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1117217/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2743827\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-29T19:26:00.263594629Z","server_sent_at_ms":1782761160263},"received_at":"2026-06-29T19:26:00.316Z","source_url":"https://www.prnewswire.com/news-releases/embecta-corp-embc-faces-securities-class-action-for-allegedly-concealing-competitive-threats-to-pen-needle-business----hbss-302813452.html"},"analysis":{"id":"65038","press_release_id":"75758","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Hagens Berman announced an investigation into Embecta regarding alleged concealment of competitive threats to its pen needle business.\n\nThe class period covers Nov. 25, 2025, to May 4, 2026, following a reported Q2 earnings miss and guidance cut that allegedly contradicted prior management assurances.\n\nInvestors with losses have an Aug. 17, 2026, deadline to seek lead plaintiff status in the class action.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"dividend_cut":"$0.01","q2_eps_actual":0.27,"new_guidance_eps":"$1.55 - $1.75","prior_guidance_eps":"$2.80 - $3.00"}},"quotedText":"Our investigation is focused the extent to which and when Embecta and its management knew about pen needle and U.S. business revenue headwinds, and whether they were sufficiently transparent about those risks,","namedEntities":{"people":[{"name":"Reed Kathrein","role":"Partner"}],"products":["pen needles","insulin pens"],"companies":[{"name":"Embecta Corp.","ticker":"EMBC"},{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.80 - $3.00","context":"2026 adjusted EPS guidance given Feb 5"},{"amount":"$0.27","context":"Q2 2026 adjusted EPS reported May 5"},{"amount":"$1.55 - $1.75","context":"reduced 2026 adjusted EPS guidance"},{"amount":"$0.01","context":"reduced dividend per share"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Hagens Berman. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"EMBC"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman announced an investigation into Embecta regarding alleged concealment of competitive threats to its pen needle business.\n\nThe class period covers Nov. 25, 2025, to May 4, 2026, following a reported Q2 earnings miss and guidance cut that allegedly contradicted prior management assurances.\n\nInvestors with losses have an Aug. 17, 2026, deadline to seek lead plaintiff status in the class action.","key_figures":{"customDimensions":{"dividend_cut":"$0.01","q2_eps_actual":0.27,"new_guidance_eps":"$1.55 - $1.75","prior_guidance_eps":"$2.80 - $3.00"}},"named_entities":{"people":[{"name":"Reed Kathrein","role":"Partner"}],"products":["pen needles","insulin pens"],"companies":[{"name":"Embecta Corp.","ticker":"EMBC"},{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.80 - $3.00","context":"2026 adjusted EPS guidance given Feb 5"},{"amount":"$0.27","context":"Q2 2026 adjusted EPS reported May 5"},{"amount":"$1.55 - $1.75","context":"reduced 2026 adjusted EPS guidance"},{"amount":"$0.01","context":"reduced dividend per share"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-29T19:28:09.656Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":129329,"modelName":"george-droid-qwen-72b"}}